A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Centre Hospitalier Universitaire Vaudois, Lausanne

Kantonsspital Graubuenden, Chur

Memorial Sloan Kettering Cancer Center, New York

UPMC Eye and Ear Institute, Pittsburgh

Thomas Jefferson University Hospital, Philadelphia

IRCCS Istituto Nazionale Tumori Milano, Milan

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville

Local Institution - 0038, Madrid

Local Institution, Madrid

Local Institution, Bordeaux

Florida Cancer Affiliates - Ocala, Ocala

West Cancer Center, Germantown

The Ohio State University Wexner Medical Center, Columbus

Local Institution, Siena

University Of Chicago Medical Center, Chicago

Local Institution, Lyon

Local Institution, Paris

University Of Texas Medical Branch Of Galveston, Galveston

Texas Oncology-Central Austin Cancer Center, Austin

Ucsf, San Francisco

Institut Gustave Roussy, Villejuif

Providence Portland Med Ctr, Portland

University Of Washington, Seattle

Beth Israel Deaconess Med Ctr, Boston

Dana Farber Cancer Institute, Boston

Massachusetts General Hospital, Boston

Juravinski Cancer Center, Hamilton

Princess Margaret Cancer Centre, Toronto

Local Institution, Nice

Local Institution, Barcelona